Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality.

Jose Miguel Rivera-CaravacaFrancisco MarínMaría Asunción Esteve-PastorMariano ValdésVicente VicenteVanessa RoldánGregory Y H Lip

Published in: International journal of clinical practice (2018)

In AF patients, the risk of bleeding is higher when antiplatelet therapy is combined with acenocoumarol, but the risk of mortality and stroke was not significantly different from that of patients taking only acenocoumarol.

Keyphrases

antiplatelet therapy
end stage renal disease
atrial fibrillation
acute coronary syndrome
percutaneous coronary intervention
ejection fraction
chronic kidney disease
prognostic factors
cardiovascular events
peritoneal dialysis
type diabetes
cardiovascular disease
patient reported outcomes
patient reported